Recent News

• 04.24.2025 - NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
• 04.11.2025 - Lucid Diagnostics Announces Closing of Public Offering of Common Stock
• 04.09.2025 - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
• 04.09.2025 - Lucid Diagnostics Announces Proposed Public Offering of Common Stock
• 04.03.2025 - Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
• 03.27.2025 - Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
• 03.24.2025 - Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.20.2025 - Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
• 03.18.2025 - Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
• 03.13.2025 - Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Recent Filings

• 04.18.2025 - PRE 14A Other preliminary proxy statements
• 04.11.2025 - 8-K Current report
• 04.11.2025 - EX-99.1 EX-99.1
• 04.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.10.2025 - EX-99.1 EX-99.1
• 04.10.2025 - 8-K Current report
• 04.09.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.24.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]